Colistimethate (Coly-Mycin M)

A cystic fibrosis patient may have died as a result of using the antibiotic Colistimethate that had been premixed by a pharmacy into a liquid for inhalation with a nebulizer. The FDA has not approved this use for Colistimethate (marketed as Coly-Mycin M and generics). However, in treating CF patients with Pseudomonas infections, colistimethate is often mixed with sterile water to form a solution just prior to inhalation via nebulizer. After mixing with sterile water and a buffer, colistimethate undergoes spontaneous hydrolysis to the bioactive form colistin. A component of colistin, polymyxin E1, is toxic to lung tissue. Premixing colistimethate into an aqueous solution and storing it for longer than 24 hours results in increased concentrations of colistin in solution, increasing the potential for lung toxicity. Both product liability and malpractice issues may be involved in a Colistimethate lawsuit.

Lawyer Fred Pritzker, has over 30 years of malpractice and product liability lawsuit experience and has recovered millions for clients. He is nationally recognized and has been interviewed by the New York Times, Wall Street Journal, and other publications. In recognition of his accomplishments, he has been selected by other lawyers for inclusion in The Best Lawyers in America.

FDA Colistimethate (Coly-Mycin M) Public Health Advisory
The FDA has received a report about the death of a patient with cystic fibrosis (CF) who used the antibiotic Colistimethate that had been premixed by a pharmacy into a liquid for inhalation with a nebulizer. Colistmethate is marketed as Coly-Mycin M and generics. A nebulizer is a device that turns liquid medicine into a mist which is breathed in by patients to deliver the medication directly to their lungs. Nebulizers are commonly used by patients with CF. The Colistimethate that was used by this patient had been prepared and dispensed by the pharmacy as a ready-to-use liquid.

Colistimethate is FDA approved only for injection into a vein or a muscle; it is not FDA approved for use as a liquid to be inhaled via nebulizer. When Colistimethate is mixed into a liquid form, the product begins to break down into other chemicals that can damage lung tissue. Colistimethate is used to treat infections caused by certain types of bacteria, including the bacteria Pseudomonas aeruginosa, a germ that is known to cause serious lung infections in patients with CF.

In light of this reported patient death, FDA offers the following recommendations:

If using the liquid form in a nebulizer, it should be used promptly after being mixed.
Patients should discard any unused pre-mixed liquid form of Colistimethate. [This is the FDA recommendation. PritzkerOlsen, P.A. recommends not using it and keeping it in a safe place until it is certain that the patient's lungs were not adversly affected by the Colistimethate. If it is discarded, valuable evidence may be lost.]
Healthcare professionals who use Colistimethate to treat patients with CF should be aware of the potential for serious and life threatening side effects from inhalation of pre-mixed, ready-to-use liquid forms of Colistimethate. The side effects are as a result of local toxicity to the lung and airway. More details of these effects are provided in the Information for Healthcare Professional.
Healthcare professionals who treat patients with CF should work out a treatment plan with their patients that best meets their needs.
Patients and/or their caregivers with questions or concerns about this advisory should contact their healthcare provider or their Cystic Fibrosis Care Center to determine how best to continue treating their infection. [Patients who have been diagnosed with lung problems after inhaling Colistimethate should also contact the law firm of Pritzker Olsen for a free consultation regarding a possible Colistimethate lawsuit. Families of patients who have died after inhaling Colistimethat should contact PritzkerOlsen, P.A. regarding a wrongful death lawsuit.]

You can find more details about Colistimethate in FDA’s Information for Healthcare Professionals and in the full prescribing information for Colistimethate.

The FDA urges both healthcare providers and patients to report side effects from medical products to MedWatch. MedWatch reports may be made by phone: 1-800-FDA-1088; fax: 1-800-FDA-0178; or via the Internet at http://www.fda.gov/medwatch/index.htm.

For liquid Colistimethate lawsuit information, including possible malpractice lawsuits against a pharmacy and prescribing doctor, please contact PritzkerOlsen, P.A. for a free consultation. Call toll-free at 1-888-377-8900 or submit the PritzkerOlsen, P.A. online consultation form.

Free Case Consultation

We are Not Paid Unless You Win

Our attorneys work on a continguency fee basis, meaning you do not have to pay our law firm for representing you unless we win you money.

Firm News

AV Preeminent Rating by Martindale-Hubbell

Attorneys Fred Pritzker and Eric Hageman have been given the highest rating by Martindale-Hubbell for attorney, AV Preeminent. An AV® certification mark is a significant rating accomplishment - a testament to the fact that a lawyer's peers rank him or her at the highest level of professional excellence.

Adjunct Teaching Position At U of M Law School

Attorney Brendan Flaherty has accepted an adjunct teaching position at the University of Minnesota Law School. For the 2011 spring semester, Flaherty will teach a course entitled "Practice and Professionalism," which will introduce students to foundational lawyering skills and professional responsibility issues.

Attorney Elliot Olsen Speaks at Conference

Attorney Elliot Olsen recently spoke at the Seventh Annual LifeScience Alley Conference in Minneapolis on Preemption and the Future of Medical Device Litigation. He appeared with Randall Pattee of Lindquist and Vennum and Jean Lance, VP of corporate legal and general counsel for Boston Scientific.

Named Super Lawyer

In recognition of their achievements, Attorneys Fred Pritzker, Elliot Olsen and Eric Hageman were named "Super Lawyers" by Law & Politics magazine. According to Super Lawyers, "The objective is to create a credible, comprehensive and diverse listing of outstanding attorneys that can be used as a resource to assist attorneys and consumers in the search for legal counsel."

Brendan Flaherty Named a Rising Star

In recognition of his achievements, Attorney Brendan Flaherty was named a 2010 Rising Star by Minnesota Law & Politics. Only 2.5 percent of the state’s lawyers are included on the list, which highlights Minnesota’s best up-and-coming legal talent.

Fred Pritzker Listed in The Best Lawyers in America

Fred Pritzker has been notified that he will again be listed in The Best Lawyers in America for his work in personal injury litigation.

This is attorney advertising. Past results do not guarantee a similar outcome. The result of each case is determined by the specific facts and the applicable law.